Background Hereditary angioedema is a rare genetic disorder characterized by acute,
intermittent, and potentially life-threatening attacks of edema of the skin and mucosa. We …

Scientific and clinical progress together with the development of effective novel therapeutic
options has engendered multiple important changes in the diagnosis and management of …

BACKGROUND: The For Angioedema Subcutaneous Treatment (FAST)-3 study was a phase
III, randomized, double-blind, placebo-controlled study of icatibant (bradykinin B 2 receptor …

Background Hereditary angioedema with C1 inhibitor deficiency is characterized by recurrent,
unpredictable swelling episodes caused by uncontrolled plasma kallikrein generation and …

Importance Current treatments for long-term prophylaxis in hereditary angioedema have
limitations. Objective To assess the efficacy of lanadelumab, a fully human monoclonal antibody …

Background Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein in
development for the prophylaxis of hereditary angioedema (HAE) attacks. Objective Our aim …

Background Hereditary angioedema (HAE) is a rare disease characterized by unpredictable,
potentially life-threatening attacks, resulting in significant physical and emotional burdens …

Background Hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) impairs
health-related quality of life (HRQoL). Objective The objective of this study was to assess HRQoL …

Hereditary angioedema (HAE) is a potentially life-threatening inherited disease characterized
by attacks of skin swelling, severe abdominal pain, and upper airway swelling. Attacks …

Background The plasma-derived, highly purified, nanofiltered C1-inhibitor concentrate (Berinert;
“pnfC1-INH”) is approved in the United States for treating hereditary angioedema (HAE) …